The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A
ADPKD
V2 receptor antagonist
blood pressure
vasopressin
Journal
Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
27
10
2020
accepted:
01
03
2021
pubmed:
24
4
2021
medline:
24
4
2021
entrez:
23
4
2021
Statut:
ppublish
Résumé
The V2 receptor antagonist tolvaptan is prescribed to patients with autosomal dominant polycystic kidney disease to slow disease progression. Tolvaptan may alter BP To investigate the magnitude and time course of the effect of tolvaptan use on BP, we conducted a At baseline, BP did not differ between study arms. After 3 weeks of tolvaptan use, mean body weight had decreased from 79.7 to 78.8 kg, and mean plasma sodium increased from 140.4 to 142.6 mmol/L (both Long-term treatment with tolvaptan gradually lowered BP compared with placebo, which may be attributed to a beneficial effect on disease progression, a continued natriuretic effect, or both. TEMPO 3:4, NCT00428948.
Sections du résumé
BACKGROUND
BACKGROUND
The V2 receptor antagonist tolvaptan is prescribed to patients with autosomal dominant polycystic kidney disease to slow disease progression. Tolvaptan may alter BP
METHODS
METHODS
To investigate the magnitude and time course of the effect of tolvaptan use on BP, we conducted a
RESULTS
RESULTS
At baseline, BP did not differ between study arms. After 3 weeks of tolvaptan use, mean body weight had decreased from 79.7 to 78.8 kg, and mean plasma sodium increased from 140.4 to 142.6 mmol/L (both
CONCLUSIONS
CONCLUSIONS
Long-term treatment with tolvaptan gradually lowered BP compared with placebo, which may be attributed to a beneficial effect on disease progression, a continued natriuretic effect, or both.
CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER
UNASSIGNED
TEMPO 3:4, NCT00428948.
Identifiants
pubmed: 33888577
pii: 00001751-202107000-00023
doi: 10.1681/ASN.2020101512
pmc: PMC8425647
doi:
Banques de données
ClinicalTrials.gov
['NCT00428948']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1801-1812Informations de copyright
Copyright © 2021 by the American Society of Nephrology.
Références
Koshimizu TA, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A: Vasopressin V1a and V1b receptors: From molecules to physiological systems. Physiol Rev 92: 1813–1864, 2012 23073632
Andersen LJ, Andersen JL, Schütten HJ, Warberg J, Bie P: Antidiuretic effect of subnormal levels of arginine vasopressin in normal humans. Am J Physiol 259: R53–R60, 1990 2375429
Bankir L: Antidiuretic action of vasopressin: Quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 51: 372–390, 2001 11476728
Henderson KK, Byron KL: Vasopressin-induced vasoconstriction: Two concentration-dependent signaling pathways. J Appl Physiol (1985) 102: 1402–1409, 2007
Mackie AR, Brueggemann LI, Henderson KK, Shiels AJ, Cribbs LL, Scrogin KE, et al.: Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance. J Pharmacol Exp Ther 325: 475–483, 2008 18272810
Nyvad J, Mazur A, Postnov DD, Straarup MS, Soendergaard AM, Staehr C, et al.: Intravital investigation of rat mesenteric small artery tone and blood flow. J Physiol 595: 5037–5053, 2017 28568894
Meijer E, Boertien WE, Zietse R, Gansevoort RT: Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease. Kidney Blood Press Res 34: 235–244, 2011 21691126
Knepper MA, Kwon TH, Nielsen S: Molecular physiology of water balance. N Engl J Med 372: 1349–1358, 2015 25830425
Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 369: 1287–1301, 2007 17434405
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al.; TEMPO 3:4 Trial Investigators: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367: 2407–2418, 2012 23121377
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al.; REPRISE Trial Investigators: Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 377: 1930–1942, 2017 29105594
Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, et al.; TEMPO 3:4 Investigators: Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney Int 96: 159–169, 2019 30898339
Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T: Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials. Cardiovasc Drug Rev 25: 1–13, 2007 17445084
Feng JJ, Arendshorst WJ: Enhanced renal vasoconstriction induced by vasopressin in SHR is mediated by V1 receptors. Am J Physiol 271: F304–F313, 1996 8770161
Cowley AW Jr, Skelton MM, Kurth TM: Effects of long-term vasopressin receptor stimulation on medullary blood flow and arterial pressure. Am J Physiol 275: R1420–R1424, 1998 9791056
Perucca J, Bichet DG, Bardoux P, Bouby N, Bankir L: Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J Am Soc Nephrol 19: 1721–1731, 2008 18596120
Bankir L, Bichet DG, Bouby N: Vasopressin V2 receptors, ENaC, and sodium reabsorption: A risk factor for hypertension? Am J Physiol Renal Physiol 299: F917–F928, 2010 20826569
Gonzalez AA, Cifuentes-Araneda F, Ibaceta-Gonzalez C, Gonzalez-Vergara A, Zamora L, Henriquez R, et al.: Vasopressin/V2 receptor stimulates renin synthesis in the collecting duct. Am J Physiol Renal Physiol 310: F284–F293, 2016 26608789
Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, et al.: Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3-4 study. Am J Kidney Dis 57: 692–699, 2011 21333426
Morgenthaler NG, Struck J, Alonso C, Bergmann A: Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52: 112–119, 2006 16269513
Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, et al.; CRISP Investigators: Imaging classification of autosomal dominant polycystic kidney disease: A simple model for selecting patients for clinical trials. J Am Soc Nephrol 26: 160–172, 2015 24904092
Papaioannou TG, Protogerou AD, Vrachatis D, Konstantonis G, Aissopou E, Argyris A, et al.: Mean arterial pressure values calculated using seven different methods and their associations with target organ deterioration in a single-center study of 1878 individuals. Hypertens Res 39: 640–647, 2016 27194570
Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, et al.; Tolvaptan Investigators: Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind, randomized trial. Circulation 107: 2690–2696, 2003 12742979
Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al.; SALT Investigators: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355: 2099–2112, 2006 17105757
Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al.; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial. JAMA 297: 1319–1331, 2007 17384437
Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T: Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 292: 288–294, 2000 10604960
Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Kodama M, et al.: Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Biochem Pharmacol 75: 1322–1330, 2008 18179782
Jujo K, Saito K, Ishida I, Furuki Y, Kim A, Suzuki Y, et al.: Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Fail 3: 177–188, 2016 27818782
Al Therwani S, Malmberg MES, Rosenbaek JB, Bech JN, Pedersen EB: Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: A randomized, placebo-controlled, double blind, crossover study. BMC Nephrol 18: 268, 2017
Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, et al.: Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 80: 295–301, 2011 21544064
Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, et al.: Short-term effects of tolvaptan in individuals with autosomal dominant polycystic kidney disease at various levels of kidney function. Am J Kidney Dis 65: 833–841, 2015 25600953
Thompson CJ, Edwards CR, Baylis PH: Osmotic and non-osmotic regulation of thirst and vasopressin secretion in patients with compulsive water drinking. Clin Endocrinol (Oxf) 35: 221–228, 1991 1742879
Smith D, Moore K, Tormey W, Baylis PH, Thompson CJ: Downward resetting of the osmotic threshold for thirst in patients with SIADH. Am J Physiol Endocrinol Metab 287: E1019–E1023, 2004 15213060
Drawz PE, Abdalla M, Rahman M: Blood pressure measurement: Clinic, home, ambulatory, and beyond. Am J Kidney Dis 60: 449–462, 2012 22521624
Howard JP, Shun-Shin MJ, Hartley A, Bhatt DL, Krum H, Francis DP: Quantifying the 3 biases that lead to unintentional overestimation of the blood pressure-lowering effect of renal denervation. Circ Cardiovasc Qual Outcomes 9: 14–22, 2016 26758193
Heida JE, Boesten LS, Ettema EM, Kobold ACM, Franssen CFM, Goosevoort RT, et al.: Comparison of ex vivo stability of copeptin and vasopressin. Clin Chem Lab Med 55: 984–992, 2016 27879483